Company Monitoring Page for Novo-Nordisk

latest headlines for company on cafepharma

The best drug is not always a guarantee for the best financial results
GoInPharma
Wed, 08/16/17 - 09:37 pm
Tags:
Novo Nordisk, Tresiba, diabetes, insulin
Novo focuses on new obesity therapy Semaglutide
GoInPharma
Tue, 08/15/17 - 09:31 am
Tags:
Novo Nordisk, obesity, semaglutide
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
Tags:
pharma stocks, Merck, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK, Roche, Sanofi, Bayer, Novo Nordisk, Celgene, Biogen, AstraZeneca
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Endpoints
Thu, 08/10/17 - 11:36 am
Tags:
Novo Nordisk, semaglutide, obesity
Novo Nordisk leans on Victoza as competition increases
BioPharma Dive
Wed, 08/9/17 - 03:09 pm
Tags:
Novo Nordisk, Victoza
Novo Nordisk profit flat; upbeat on sales outlook
Marketwatch
Wed, 08/9/17 - 11:15 am
Tags:
Novo Nordisk, earnings
Diabetes drugmakers partner with mobile startups to boost patient engagement
Medical Marketing and Media
Fri, 07/21/17 - 10:03 am
Tags:
diabetes, mobile apps, patients, Novo Nordisk, Glooko, Roche, mySugr
Puma's FDA Decider And Semaglutide's Head-To-Head Battle
Seeking Alpha
Mon, 07/10/17 - 11:09 am
Tags:
Puma Biotechnology, FDA, Novo Nordisk, Nerlynx, neratinib, semaglutide
Novo Nordisk Warns of Possible Cracks in Insulin Devices
RAPS.org
Wed, 07/5/17 - 07:17 pm
Tags:
Novo Nordisk, insulin, diabetes, devices, NovoPen Echo
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Drug Delivery Business News
Tue, 07/4/17 - 11:18 pm
Tags:
Novo Nordisk, Tresiba, insulin, clinical trials, diabetes
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Reuters
Mon, 06/26/17 - 05:15 pm
Tags:
Novo Nordisk, obesity, semaglutide
What we know from BIO2017
BioPharma Dive
Fri, 06/23/17 - 11:30 am
Tags:
BIO2017, M&A, Novartis, Novo Nordisk, Seattle Genetics, ImmunoCellular Therapeutics
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
Medical Marketing and Media
Thu, 06/22/17 - 09:32 am
Tags:
diabetes, blood sugar, competition, Novo Nordisk, Victoza, Eli Lilly, Jardiance, Invokana, JNJ
FDA panel supports cardiovascular indication for Novo’s diabetes drug Victoza
Fierce Pharma
Tue, 06/20/17 - 10:53 pm
Tags:
FDA, advisory panels, Novo Nordisk, diabetes, Victoza
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Fierce Pharma
Fri, 06/16/17 - 09:35 am
Tags:
Novo Nordisk, Lantus, Tresiba, diabetes, Europe, EMA, insulin
ADA preview: 5 things to watch in diabetes
BioPharma Dive
Sun, 06/11/17 - 09:30 am
Tags:
ADA, diabetes, Jardiance, Eli Lilly, Boehringer Ingelheim, Lantus, Tresiba, JNJ, Novo Nordisk, PCSK9 inhibitors, Amgen Regeneron, Sanofi, Apple, Google, insulin
Why Novo Nordisk A/S (ADR) Jumped 10.6% In May
Motley Fool
Sun, 06/11/17 - 09:13 am
Tags:
Novo Nordisk, drug pricing, diabetes
Top 10 diabetes drugs by 2016 sales
Fierce Pharma
Thu, 06/8/17 - 10:04 am
Tags:
diabetes, Sanofi, Novo Nordisk, Eli Lilly, Merck, Lantus, Januvia, Victoza, Levemir, Humalog, Novolog, Invokana
AbbVie, Novo Nordisk and Takeda Have the Best Reputations Among Pharma Companies According to Reputation Institute Global Pharma Reptrak® Study
PR Web
Thu, 06/1/17 - 09:19 am
Tags:
reputation, AbbVie, Novo Nordisk, Takeda
Novo Nordisk seeks to include cardiovascular data in Tresiba insulin label
Drug Delivery Business News
Tue, 05/30/17 - 06:17 pm
Tags:
Novo Nordisk, diabetes, FDA, Tresiba, insulin

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.